Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
lifitegrast
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01XA25
|
| gptkbp:form |
eye drops
|
| gptkbp:genericName |
lifitegrast
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xiidra
|
| gptkbp:manufacturer |
gptkb:Shire
gptkb:Novartis |
| gptkbp:mechanismOfAction |
LFA-1 antagonist
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:sideEffect |
eye irritation
dysgeusia reduced visual acuity |
| gptkbp:usedFor |
gptkb:dry_eye_disease
|
| gptkbp:bfsParent |
gptkb:Takeda
|
| gptkbp:bfsLayer |
6
|